The Cell Therapy Podcast

Tumour-infiltrating lymphocyte (TIL) therapy have been a stable of cell therapy for many years and how recently shown clinical effect in phase III studies. How are TILs made, what are the major challenges the therapy face, and what’s next? In this episode we are joined by Dr Özcan Met, an associated professor at Herlev og Gentofte Hospital, Center for Cancer Immune Therapy (CCIT), Copenhagen Unive...

In this episode we interview Dr. Johanna Olweus and Dr. Morten Milek Nielsen from University of Oslo about the use of T cell receptors (TCR’s) as immunotherapy against cancer.   Dr. Olweus’s group has been speadheading identifying TCRs that are specific for minute mutations in cancer cells, that can be used in adoptive T-cell-based therapies. We talk about what the therapy entails, how TCRs are di...

In this episode we talk to Dr. Rasmus O Bak from Aarhus University about the use of CRISPR and its use in cellular therapies. CRISPR has now become a method to not only knock gene’s out but - as Dr. Bak explains - also an all-round tool that can be utilized to a variety of different task.  We discuss research from Dr. Bak’s research group, examining how CRISPRa and CRISPRi - a method to either act...

What are NK cells, how do they function and how can we utilize them as a cellular therapy? In this episode we are joined by Dr Arnika K. Wagner and Dr Evren Alici, both from Center for Hematology and Regenerative Medicine at Karolinska Institutet, and Dr Sigrid Skånland from Institute for Cancer Research at Olso University Hospital for a chat about these exciting cells and how their anti-cancer ef...

What is precision medicine? How can cancer patients benefit from it, and what role does it play in cellular therapy? In this episode our guests Dr Caroline Heckman (Research Director for Institute for Molecular Medicine at University of Helsinki) and Dr Kjetil Tasken (Director, OUH Centre for Precision Medicine in Cancer at Oslo University Hospital) explore the role of precision medicine in hemato...

Chimeric antigen receptor therapy has revolutionized hematology but is there ways we could further improve the immune cells that delivery the therapy? In this episode we talk to Professor Satu Mustjoki and Dr Olli Dufva and their recent paper ‘Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity’ (Link: https://ashpublications.org/blood/article/135...

Solid tumour cells often use receptors such as PDL1 to block killing from immune cells. In this episode of the Cell Therapy Podcast we talk with Sébastien Wälchli, senior scientist at the Section for Cellular Therapy, Radiumhospitalet in Oslo, Norway about ways to bypass this cancer cell defense and how to improve CAR T cell therapy using combinatorial CARs. We discuss two recent papers from Dr Wä...

How can we trick cancer cells into revealing new antigens; and whats the next cell-type for adoptive therapies? In this first episode of the Cell Therapy Podcast we talk with Sine Reker Hadrup, professor at Technical University of Denmark about her one of her latest articles in Nature Communication called ‘Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers’ (...